Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 116


Identifying clinical improvement in consolidation single-arm phase 2 trials in patients with ovarian cancer in second or greater clinical remission.

Iasonos A, Sabbatini P, Spriggs DR, Aghajanian CA, O'Cearbhaill RE, Hensley ML, Thaler HT.

Int J Gynecol Cancer. 2012 Jan;22(1):63-9. doi: 10.1097/IGC.0b013e31822e29aa.


Comparison of error rates in single-arm versus randomized phase II cancer clinical trials.

Tang H, Foster NR, Grothey A, Ansell SM, Goldberg RM, Sargent DJ.

J Clin Oncol. 2010 Apr 10;28(11):1936-41. doi: 10.1200/JCO.2009.25.5489. Epub 2010 Mar 8.


Long-term survival with consolidation intraperitoneal chemotherapy for patients with advanced ovarian cancer with pathological complete remission.

Tournigand C, Louvet C, Molitor JL, Fritel X, Dehni N, Sezeur A, Pigné A, Cady J, Milliez J, de Gramont A.

Gynecol Oncol. 2003 Nov;91(2):341-5.


A method for utilizing co-primary efficacy outcome measures to screen regimens for activity in two-stage Phase II clinical trials.

Sill MW, Rubinstein L, Litwin S, Yothers G.

Clin Trials. 2012 Aug;9(4):385-95. doi: 10.1177/1740774512450101. Epub 2012 Jul 18.


Alemtuzumab for patients with chronic lymphocytic leukaemia.

Skoetz N, Bauer K, Elter T, Monsef I, Roloff V, Hallek M, Engert A.

Cochrane Database Syst Rev. 2012 Feb 15;2:CD008078. doi: 10.1002/14651858.CD008078.pub2. Review.


Quantitative evaluation of single-arm versus randomized phase II cancer clinical trials.

Pond GR, Abbasi S.

Clin Trials. 2011 Jun;8(3):260-9. doi: 10.1177/1740774511401764. Epub 2011 Apr 20.


Maintenance chemotherapy for ovarian cancer.

Mei L, Chen H, Wei DM, Fang F, Liu GJ, Xie HY, Wang X, Zou J, Han X, Feng D.

Cochrane Database Syst Rev. 2013 Jun 29;6:CD007414. doi: 10.1002/14651858.CD007414.pub3. Review.


Timing isn't everything: an analysis of when to start salvage chemotherapy in ovarian cancer.

McMeekin DS, Tillmanns T, Chaudry T, Gold M, Johnson G, Walker J, Mannel R.

Gynecol Oncol. 2004 Oct;95(1):157-64.


A phase II, randomized, placebo-controlled study of vismodegib as maintenance therapy in patients with ovarian cancer in second or third complete remission.

Kaye SB, Fehrenbacher L, Holloway R, Amit A, Karlan B, Slomovitz B, Sabbatini P, Fu L, Yauch RL, Chang I, Reddy JC.

Clin Cancer Res. 2012 Dec 1;18(23):6509-18. doi: 10.1158/1078-0432.CCR-12-1796. Epub 2012 Oct 2.


Maintenance chemotherapy for ovarian cancer.

Mei L, Chen H, Wei DM, Fang F, Liu GJ, Xie HY, Wang X, Zou J, Han X, Feng D.

Cochrane Database Syst Rev. 2010 Sep 8;(9):CD007414. doi: 10.1002/14651858.CD007414.pub2. Review. Update in: Cochrane Database Syst Rev. 2013;6:CD007414.


Rituximab, ofatumumab and other monoclonal anti-CD20 antibodies for chronic lymphocytic leukaemia.

Bauer K, Rancea M, Roloff V, Elter T, Hallek M, Engert A, Skoetz N.

Cochrane Database Syst Rev. 2012 Nov 14;11:CD008079. doi: 10.1002/14651858.CD008079.pub2. Review.


90Yttrium-ibritumomab tiuxetan consolidation of first remission in advanced-stage follicular non-Hodgkin lymphoma: updated results after a median follow-up of 7.3 years from the International, Randomized, Phase III First-LineIndolent trial.

Morschhauser F, Radford J, Van Hoof A, Botto B, Rohatiner AZ, Salles G, Soubeyran P, Tilly H, Bischof-Delaloye A, van Putten WL, Kylstra JW, Hagenbeek A.

J Clin Oncol. 2013 Jun 1;31(16):1977-83. doi: 10.1200/JCO.2012.45.6400. Epub 2013 Apr 1.


Efficacy and safety results from OCTAVIA, a single-arm phase II study evaluating front-line bevacizumab, carboplatin and weekly paclitaxel for ovarian cancer.

Gonzalez-Martin A, Gladieff L, Tholander B, Stroyakovsky D, Gore M, Scambia G, Kovalenko N, Oaknin A, Ronco JP, Freudensprung U, Pignata S; OCTAVIA Investigators.

Eur J Cancer. 2013 Dec;49(18):3831-8. doi: 10.1016/j.ejca.2013.08.002. Epub 2013 Sep 2.


Topotecan compared with no therapy after response to surgery and carboplatin/paclitaxel in patients with ovarian cancer: Multicenter Italian Trials in Ovarian Cancer (MITO-1) randomized study.

De Placido S, Scambia G, Di Vagno G, Naglieri E, Lombardi AV, Biamonte R, Marinaccio M, Cartenì G, Manzione L, Febbraro A, De Matteis A, Gasparini G, Valerio MR, Danese S, Perrone F, Lauria R, De Laurentiis M, Greggi S, Gallo C, Pignata S.

J Clin Oncol. 2004 Jul 1;22(13):2635-42.


A phase II evaluation of goserelin and bicalutamide in patients with ovarian cancer in second or higher complete clinical disease remission.

Levine D, Park K, Juretzka M, Esch J, Hensley M, Aghajanian C, Lewin S, Konner J, Derosa F, Spriggs D, Iasonos A, Sabbatini P.

Cancer. 2007 Dec 1;110(11):2448-56.


Double-blind, randomized, phase 2 trial of maintenance sunitinib versus placebo after response to chemotherapy in patients with advanced urothelial carcinoma.

Grivas PD, Daignault S, Tagawa ST, Nanus DM, Stadler WM, Dreicer R, Kohli M, Petrylak DP, Vaughn DJ, Bylow KA, Wong SG, Sottnik JL, Keller ET, Al-Hawary M, Smith DC, Hussain M.

Cancer. 2014 Mar 1;120(5):692-701. doi: 10.1002/cncr.28477. Epub 2013 Nov 18.


Efficacy and safety of topotecan in the treatment of advanced ovarian carcinoma.

ten Bokkel Huinink W, Carmichael J, Armstrong D, Gordon A, Malfetano J.

Semin Oncol. 1997 Feb;24(1 Suppl 5):S5-19-S5-25. Review.


Continued chemotherapy after complete response to primary therapy among women with advanced ovarian cancer: a meta-analysis.

Hess LM, Rong N, Monahan PO, Gupta P, Thomaskutty C, Matei D.

Cancer. 2010 Nov 15;116(22):5251-60. doi: 10.1002/cncr.25487.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk